Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00431210 · ClinicalTrials.gov registry record · Phase 1
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
A Phase 1 study of Nasopharyngeal Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT00431210 is a Phase 1 study of Nasopharyngeal Carcinoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 28 participants, below the 96-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00431210, a Phase 1 study of Nasopharyngeal Carcinoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the body. EBV immunotherapy product is made with white blood cells from the participants body that are collected intravenously. This EBV immunotherapy product may stop cancer cells from growing abnormally. EBV immunotherapy products have been used in several research studies for NPC. Information from these studies suggests the EBV immunotherapy products may stop the growth of NPC in some subjects.
Conditions Studied
Interventions
- BIOLOGICAL Epstein-Barr virus-specific adoptive T-cells immunotherapy
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-02 |
| Est. Completion | 2016-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00431210
The ClinicalTrials.gov registry entry for NCT00431210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (71% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nasopharyngeal Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Epstein-Barr virus-specific adoptive T-cells immunotherapy is the first listed.
NCT00431210 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00431210 about?
NCT00431210 is a clinical study titled "Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma". The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the body. EBV immunotherapy product is made with white blood ce...
What is the current status of trial NCT00431210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2007-02. Estimated completion is 2016-01-26.
What conditions does trial NCT00431210 study?
This clinical trial studies the following conditions: Nasopharyngeal Carcinoma.
What interventions are being tested in trial NCT00431210?
The interventions under investigation include: Epstein-Barr virus-specific adoptive T-cells immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00431210?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00431210 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasopharyngeal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
ACTIVE NOT RECRUITING · Phase 1
-
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
ACTIVE NOT RECRUITING · Phase 1
-
LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
COMPLETED · Phase 1
-
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
RECRUITING · Phase 2
-
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.